abrdn Life Sciences Investors
HQL
$13.09
$0.070.54%
Weiss Ratings | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Fair | |||
Reward Grade | C | |||
Risk Index | Fair | |||
Risk Grade | C- | |||
Company Info | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Provider | abrdn Inc. | |||
Manager/Tenure (Years) | Jason C. Akus (1) | |||
Website | http://www.abrdn.com/us | |||
Fund Information | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Fund Name | abrdn Life Sciences Investors | |||
Category | Health | |||
Sub-Category | Healthcare Sector Equity | |||
Prospectus Objective | Specialty - Health | |||
Inception Date | May 08, 1992 | |||
Open/Closed To New Investors | Open | |||
Minimum Initial Investment | -- | |||
Minimum Subsequent Investment | -- | |||
Front End Fee | -- | |||
Back End Fee | -- | |||
Dividends and Shares | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Yield | 4.38% | |||
Dividend | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Yield (Forward) | 0.37% | |||
Asset Allocation | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Cash | 4.74% | |||
Stock | 87.32% | |||
U.S. Stock | 76.12% | |||
Non-U.S. Stock | 11.20% | |||
Bond | 0.00% | |||
U.S. Bond | 0.00% | |||
Non-U.S. Bond | 0.00% | |||
Preferred | 7.12% | |||
Convertible | 0.27% | |||
Other Net | 0.56% | |||
Price History | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | -0.31% | |||
30-Day Total Return | 4.95% | |||
60-Day Total Return | 0.76% | |||
90-Day Total Return | 6.83% | |||
Year to Date Total Return | -0.10% | |||
1-Year Total Return | -1.70% | |||
2-Year Total Return | 11.05% | |||
3-Year Total Return | 20.86% | |||
5-Year Total Return | 7.01% | |||
Price | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Closing Price | -- | |||
1-Month Low Price | $12.31 | |||
1-Month High Price | $13.02 | |||
52-Week Low Price | $10.87 | |||
52-Week Low Price (Date) | Apr 08, 2025 | |||
52-Week High Price | $15.78 | |||
52-Week High Price (Date) | Aug 21, 2024 | |||
NAV | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Nav | $14.03 | |||
1-Month Low NAV | $13.70 | |||
1-Month High NAV | $14.47 | |||
52-Week Low NAV | $12.00 | |||
52-Week Low NAV (Date) | Apr 08, 2025 | |||
52-Week High NAV | $17.36 | |||
52-Week High Price (Date) | Aug 21, 2024 | |||
Beta / Standard Deviation | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Beta | 0.87 | |||
Standard Deviation | 14.37 | |||
Balance Sheet | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Total Assets | 410.08M | |||
Operating Ratios | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Expense Ratio | 1.35% | |||
Turnover Ratio | 46.00% | |||
Performance | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Last Bull Market Total Return | 13.58% | |||
Last Bear Market Total Return | -8.89% | |||